-
Mashup Score: 0Race, sex disparities persist in weight-loss surgery - 3 hour(s) ago
Men were less likely than women to have weight-loss surgery, and that gap has widened over time, while Black patients were less likely than those of other races to have a procedure, and that gap has narrowed slightly, new data show. “Metabolic/bariatric surgery is a safe and very effective treatment of obesity,” Alexander Turchin, MD, MS, director of quality in diabetes at Brigham and
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 0Race, sex disparities persist in weight-loss surgery - 11 hour(s) ago
Men were less likely than women to have weight-loss surgery, and that gap has widened over time, while Black patients were less likely than those of other races to have a procedure, and that gap has narrowed slightly, new data show. “Metabolic/bariatric surgery is a safe and very effective treatment of obesity,” Alexander Turchin, MD, MS, director of quality in diabetes at Brigham and
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
📰Researchers found several disparities with bariatric surgery, including that men are less likely to undergo surgery than women; and Black adults are less likely to have surgery than other racial-ethnic groups. @BrighamWomens @harvardmed @MarsApovian https://t.co/EMhJPKrWSX
-
-
Mashup Score: 8
A new international commission report has proposed new criteria for diagnosing obesity that could dramatically change the way it is categorized and managed in the future. The Lancet Diabetes & Endocrinology Commission comprises 58 experts from around the world who were convened as part of a group to develop new recommendations for defining and diagnosing obesity. Francesco Rubino,
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
📖A new report from a @TheLancetEndo Commission is poised to transform the way health care professionals define, diagnose and manage #obesity. Hear from some of the commission members and learn about the biggest changes 👇 @FRubino @askdrfatima https://t.co/w9mry9ugL0
-
-
Mashup Score: 8
A new international commission report has proposed new criteria for diagnosing obesity that could dramatically change the way it is categorized and managed in the future. The Lancet Diabetes & Endocrinology Commission comprises 58 experts from around the world who were convened as part of a group to develop new recommendations for defining and diagnosing obesity. Francesco Rubino,
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
📖A new report from a @TheLancetEndo Commission is poised to transform the way health care professionals define, diagnose and manage #obesity. Hear from some of the commission members and learn about the biggest changes 👇 @FRubino @askdrfatima https://t.co/w9mry9ugL0
-
-
Mashup Score: 0
Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a DPP-IV inhibitor, according to findings published in Thyroid. Researchers collected data from adults aged 40 years and older with type 2 diabetes from Canada, Denmark, Norway, South Korea, Sweden and Taiwan who filled a prescription for a GLP-1 receptor agonist (n =
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
💊 Data from six national databases revealed #GLP1 medications are not tied to an increased risk for #thyroid cancer for adults with type 2 #diabetes. Learn more 👇 @UniSouthDenmark @HemOncToday https://t.co/iLtYcSRCZ0
-
-
Mashup Score: 0
Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a DPP-IV inhibitor, according to findings published in Thyroid. Researchers collected data from adults aged 40 years and older with type 2 diabetes from Canada, Denmark, Norway, South Korea, Sweden and Taiwan who filled a prescription for a GLP-1 receptor agonist (n =
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
💊 Data from six national databases revealed #GLP1 medications are not tied to an increased risk for #thyroid cancer for adults with type 2 #diabetes. Learn more 👇 @UniSouthDenmark @HemOncToday https://t.co/iLtYcSRCZ0
-
-
Mashup Score: 1
For the second time since 2019, the oral SGLT1 and SGLT2 dual inhibitor sotagliflozin has been denied FDA approval for adults with type 1 diabetes, with elevated risk for diabetic ketoacidosis being a primary concern.Lexicon Pharmaceuticals acknowledged the receipt of an FDA complete response letter for sotagliflozin (Zynquista, Lexicon) in a press release on Dec. 20. The company had filed a new
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
📣 On Dec. 20, the @US_FDA issued a complete response letter for sotagliflozin to treat type 1 #diabetes and #CKD on Dec. 20. Several experts share their thoughts on the decision and what it means for people with #T1D. @Nephronline https://t.co/ZhLw0KPZFl
-
-
Mashup Score: 1
For the second time since 2019, the oral SGLT1 and SGLT2 dual inhibitor sotagliflozin has been denied FDA approval for adults with type 1 diabetes, with elevated risk for diabetic ketoacidosis being a primary concern.Lexicon Pharmaceuticals acknowledged the receipt of an FDA complete response letter for sotagliflozin (Zynquista, Lexicon) in a press release on Dec. 20. The company had filed a new
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
📣 On Dec. 20, the @US_FDA issued a complete response letter for sotagliflozin to treat type 1 #diabetes and #CKD on Dec. 20. Several experts share their thoughts on the decision and what it means for people with #T1D. @Nephronline https://t.co/ZhLw0KPZFl
-
-
Mashup Score: 4The year in obesity: New data on semaglutide and tirzepatide, sarcopenic obesity and more - 6 day(s) ago
New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in October, Robert H. Eckel, MD, professor of medicine, emeritus in the division of endocrinology, metabolism and diabetes and division of cardiology, the Charles A. Boettcher II Chair in
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
📖Miss out on any of the biggest #obesity studies from 2024? We have you covered with this presentation from Robert Eckel, MD, of @CUAnschutz at #CMHC19thAnnual. @CMHC_CME @CardiologyToday https://t.co/ukmDrJBChV
-
-
Mashup Score: 8
Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by approximately 20% at 1 year in patients with overweight or obesity, according to a presentation.Results from a double-blind, dose-ranging phase 2 study of maridebart cafraglutide (MariTide, Amgen) were presented at the World Congress on Insulin Resistance, Diabetes and Cardiovascular
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
📣Maridebart cafraglutide reduced body weight by about 20% and improved other cardiometabolic parameters in adults with overweight or #obesity in a phase 2 trial, according to data presented at #WCIRDC24. @WCIRDC @YHandelsmanMD @CardiologyToday @Amgen https://t.co/wgjofwnEs1
-
📰Researchers found several disparities with bariatric surgery, including that men are less likely to undergo surgery than women; and Black adults are less likely to have surgery than other racial-ethnic groups. @BrighamWomens @harvardmed @MarsApovian https://t.co/EMhJPKrWSX